No business profile yet.
Size Oneness Biotech (4743.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $580M, the 389th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$43.80 on 18 Nov 2026.
Performance Over six months the shares fell 12.9%, against -24.7% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 18.7% over the last twelve months (peer median -1.7%); the operating margin is -589.3% (peer median 5.6%).
Valuation It trades at 101.5× enterprise value to sales against a peer median of 3.1× (most expensive of 17).
Capital Return on invested capital runs 18.4 points below its cost of capital (5.6% WACC).
Next results Next results expected around 19 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$140M | NT$125M | NT$117M | NT$86.8M | NT$1.07B |
| Revenue growth | — | +7% | +35% | -92% | — |
| Gross profit | -NT$242M | -NT$261M | -NT$362M | -NT$382M | NT$552M |
| EBITDA | -NT$503M | -NT$469M | -NT$632M | -NT$648M | NT$250M |
| Net income | -NT$216M | -NT$1.04B | -NT$1.17B | -NT$1.31B | NT$360M |
| Free cash flow | -NT$233M | -NT$471M | -NT$392M | -NT$485M | -NT$937M |
| Capital expenditure | NT$16.3M | NT$26.5M | NT$53.3M | NT$90.9M | NT$89.2M |
| Total debt | NT$338M | NT$371M | NT$406M | NT$432M | NT$263M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4743.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.5% | -11.1% | 10th lowest of 21 |
| 6-month return | -12.9% | -24.7% | 5th highest of 21 |
| Distance from 52-week high | -42.9% | -44.0% | 10th highest of 21 |
| Revenue growth (TTM) | +18.7% | -1.7% | 4th highest of 18 |
| Operating margin | -589.3% | 5.6% | 3rd lowest of 17 |
| EV / Sales | 101.5× | 3.1× | most expensive of 17 |
| ROIC minus cost of capital | -18.4 pp | -2.7 pp | 3rd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | 101.5× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 4.5× | n/a | n/a |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | 20.1× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 2.6× | 20.9% | +21.9% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | 23.9× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | 3.7× | 50.4% | -12.3% |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 8.7× | 36.4% | +11.2% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 7.5× | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |